These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21933888)

  • 21. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
    Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
    Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
    Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dual inhibition of apoptosis and autophagy in prostate cancer.
    Saleem A; Dvorzhinski D; Santanam U; Mathew R; Bray K; Stein M; White E; DiPaola RS
    Prostate; 2012 Sep; 72(12):1374-81. PubMed ID: 22241682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABT-737 potentiates cisplatin-induced apoptosis in human osteosarcoma cells via the mitochondrial apoptotic pathway.
    Zhang F; Yu X; Liu X; Zhou T; Nie T; Cheng M; Liu H; Dai M; Zhang B
    Oncol Rep; 2017 Oct; 38(4):2301-2308. PubMed ID: 28849162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells.
    Yin P; Jia J; Li J; Song Y; Zhang Y; Chen F
    Oncol Res; 2016; 24(1):65-72. PubMed ID: 27178823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.
    Mukherjee N; Reuland SN; Lu Y; Luo Y; Lambert K; Fujita M; Robinson WA; Robinson SE; Norris DA; Shellman YG
    J Invest Dermatol; 2015 Mar; 135(3):842-850. PubMed ID: 25350317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
    Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
    Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
    He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
    Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
    Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
    Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.
    Li JY; Li YY; Jin W; Yang Q; Shao ZM; Tian XS
    J Exp Clin Cancer Res; 2012 Dec; 31(1):102. PubMed ID: 23259599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo.
    Sun XP; Zhang X; He C; Qiao H; Jiang X; Jiang H; Sun X
    J Int Med Res; 2012; 40(4):1251-64. PubMed ID: 22971477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
    Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
    J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.